Does tumour dormancy offer a therapeutic target?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21048784.
- Also identified by DOI 10.1038/nrc2933.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The increasing number of cancer survivors is cause for celebration, but this expanding population has highlighted the problem of tumour dormancy, which can lead to relapse. As we start to understand more about the biology of dormant cancer cells, we can begin to address how best to treat this form of disease. Preclinical models and initial clinical trials, as exemplified in patients with breast cancer, are paving the way to address how best to treat long-term cancer survivors to minimize the risk of cancer recurrence.
Medical subject headings
- Breast Neoplasms